Paula Rozenfeld

1.4k total citations
49 papers, 923 citations indexed

About

Paula Rozenfeld is a scholar working on Physiology, Cell Biology and Epidemiology. According to data from OpenAlex, Paula Rozenfeld has authored 49 papers receiving a total of 923 indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Physiology, 15 papers in Cell Biology and 14 papers in Epidemiology. Recurrent topics in Paula Rozenfeld's work include Lysosomal Storage Disorders Research (44 papers), Cellular transport and secretion (14 papers) and Trypanosoma species research and implications (13 papers). Paula Rozenfeld is often cited by papers focused on Lysosomal Storage Disorders Research (44 papers), Cellular transport and secretion (14 papers) and Trypanosoma species research and implications (13 papers). Paula Rozenfeld collaborates with scholars based in Argentina, Italy and Spain. Paula Rozenfeld's co-authors include Sandro Feriozzi, Carlos A. Fossati, Juan M. Mucci, Pablo N. De Francesco, Guillermo Docena, Marı́a Cristina Añón, Constanza Bondar, Ricardo Reisin, Isaac Kisinovsky and Tomás F. Cianciulli and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and International Journal of Molecular Sciences.

In The Last Decade

Paula Rozenfeld

45 papers receiving 893 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Paula Rozenfeld Argentina 16 698 241 230 225 142 49 923
Maira Graeff Burin Brazil 21 918 1.3× 388 1.6× 173 0.8× 239 1.1× 185 1.3× 65 1.1k
Manfred W. Ziegenhagen Germany 15 631 0.9× 140 0.6× 35 0.2× 201 0.9× 19 0.1× 23 1.1k
S. Marina Casalino‐Matsuda United States 14 143 0.2× 77 0.3× 240 1.0× 288 1.3× 28 0.2× 29 829
Nora Müller Germany 18 65 0.1× 113 0.5× 66 0.3× 239 1.1× 13 0.1× 26 913
Asunción Martínez‐Antón Spain 15 215 0.3× 59 0.2× 64 0.3× 219 1.0× 12 0.1× 19 740
Gen Isshiki Japan 19 141 0.2× 86 0.4× 35 0.2× 267 1.2× 36 0.3× 70 858
H. Jorn Bovenschen Netherlands 13 103 0.1× 86 0.4× 62 0.3× 129 0.6× 8 0.1× 29 921
Teruaki Nishiuma Japan 18 222 0.3× 52 0.2× 84 0.4× 457 2.0× 9 0.1× 42 964
Thomas Trian France 19 550 0.8× 96 0.4× 65 0.3× 384 1.7× 7 0.0× 40 1.1k
Angelo Massimiliano D’Erme Italy 13 160 0.2× 79 0.3× 99 0.4× 77 0.3× 5 0.0× 48 898

Countries citing papers authored by Paula Rozenfeld

Since Specialization
Citations

This map shows the geographic impact of Paula Rozenfeld's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paula Rozenfeld with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paula Rozenfeld more than expected).

Fields of papers citing papers by Paula Rozenfeld

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paula Rozenfeld. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paula Rozenfeld. The network helps show where Paula Rozenfeld may publish in the future.

Co-authorship network of co-authors of Paula Rozenfeld

This figure shows the co-authorship network connecting the top 25 collaborators of Paula Rozenfeld. A scholar is included among the top collaborators of Paula Rozenfeld based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paula Rozenfeld. Paula Rozenfeld is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Galmarini, Carlos M., et al.. (2025). Hereditary angioedema diagnosis evaluation score (HADES): A new clinical scoring system for predicting hereditary angioedema with C1 inhibitor deficiency. Journal of Allergy and Clinical Immunology Global. 4(2). 100414–100414.
2.
Rozenfeld, Paula, Sandro Feriozzi, & Fabian Braun. (2024). The role of tubular cells in the pathogenesis of Fabry nephropathy. Frontiers in Cardiovascular Medicine. 11. 1386042–1386042. 2 indexed citations
3.
Chain, Cecilia Y., et al.. (2024). Effective encapsulation of therapeutic recombinant enzyme into polymeric nanoparticles as a potential vehicle for lysosomal disease treatment. International Journal of Biological Macromolecules. 285. 138248–138248.
4.
Bondar, Constanza, et al.. (2024). Pathogenic pathways of renal damage in Fabry nephropathy: interplay between immune cell infiltration, apoptosis and fibrosis. Journal of Nephrology. 37(3). 625–634. 1 indexed citations
5.
Giugliani, Roberto, et al.. (2022). Opportunities and challenges for newborn screening and early diagnosis of rare diseases in Latin America. Frontiers in Genetics. 13. 1053559–1053559. 22 indexed citations
6.
Dardis, Andrea, Helen Michelakakis, Paula Rozenfeld, et al.. (2022). Patient centered guidelines for the laboratory diagnosis of Gaucher disease type 1. Orphanet Journal of Rare Diseases. 17(1). 442–442. 30 indexed citations
7.
Rozenfeld, Paula, et al.. (2021). New mutation in Fabry disease: c.448delG, first phenotypic description. Molecular Genetics and Metabolism Reports. 27. 100708–100708. 1 indexed citations
8.
Rozenfeld, Paula, et al.. (2020). Unraveling the mystery of Gaucher bone density pathophysiology. Molecular Genetics and Metabolism. 132(2). 76–85. 11 indexed citations
9.
Reisin, Ricardo, Paula Rozenfeld, & Pablo Bonardo. (2020). Fabry disease patients have an increased risk of stroke in the COVID-19 ERA. A hypothesis. Medical Hypotheses. 144. 110282–110282. 5 indexed citations
10.
Rozenfeld, Paula, et al.. (2020). Upregulation of ASIC1a channels in an in vitro model of Fabry disease. Neurochemistry International. 140. 104824–104824. 12 indexed citations
11.
Rozenfeld, Paula, et al.. (2019). Pathogenesis of Fabry nephropathy: The pathways leading to fibrosis. Molecular Genetics and Metabolism. 129(2). 132–141. 32 indexed citations
12.
Ciocca, Mirta, et al.. (2017). Liver disease and dyslipidemia as a manifestation of lysosomal acid lipase deficiency (LAL-D). Clinical and diagnostic aspects, and a new treatment. An update. Archivos Argentinos de Pediatria. 115(3). 287–293. 12 indexed citations
13.
14.
Rozenfeld, Paula & Sandro Feriozzi. (2017). Contribution of inflammatory pathways to Fabry disease pathogenesis. Molecular Genetics and Metabolism. 122(3). 19–27. 161 indexed citations
15.
Amartino, Hernán, et al.. (2014). Identification of 17 novel mutations in 40 Argentinean unrelated families with mucopolysaccharidosis type II (Hunter syndrome). Molecular Genetics and Metabolism Reports. 1. 401–406. 9 indexed citations
16.
Mucci, Juan M., et al.. (2013). Uncoupling of osteoblast–osteoclast regulation in a chemical murine model of Gaucher disease. Gene. 532(2). 186–191. 20 indexed citations
17.
Francesco, Pablo N. De, et al.. (2011). Higher apoptotic state in Fabry disease peripheral blood mononuclear cells.. Molecular Genetics and Metabolism. 104(3). 319–324. 31 indexed citations
19.
Rozenfeld, Paula. (2009). Fabry Disease: Treatment and diagnosis. IUBMB Life. 61(11). 1043–1050. 15 indexed citations
20.
Rozenfeld, Paula, et al.. (2007). Manifestaciones nefrológicas de pacientes con enfermedad de Fabry en Argentina. 27(3). 99–102.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026